In addition, programmable bacteria can be designed to selectively grow or release therapeutic payloads in response to tumor-associated stimuli [77,78], as has been demonstrated for the delivery of nanobodies against PD-L1 and CTLA-4 in the CT26 subcutaneous tumor model [77]. This evidence concerns the gene CD274 and neoplasm.